Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target - PubMed (original) (raw)

Review

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target

J G Boyle et al. Diabet Med. 2010 Oct.

Abstract

Clinical studies in Type 2 diabetes mellitus have shown that the effects of metformin go beyond improving HbA(1c) and include reductions in cardiovascular endpoints. Metformin therapy has been widely used in the treatment of Type 2 diabetes for many years, yet the precise mode of action remains uncertain. It has recently been proposed that metformin-mediated stimulation of hepatic AMP-activated protein kinase (AMPK) underlies the hypoglycaemic effects of metformin. AMPK is a heterotrimeric enzyme that is expressed in many tissues and plays a central role in the regulation of energy homoeostasis. Furthermore, there is increasing evidence that AMPK is implicated in the pathophysiology of cardiovascular and metabolic diseases. The generation of more specific and potent activators of AMPK, however, could have additional metabolic and vascular benefits for patients with Type 2 diabetes.

PubMed Disclaimer

Cited by

Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.
Murff HJ, Roumie CL, Greevy RA, Hackstadt AJ, McGowan LED, Hung AM, Grijalva CG, Griffin MR. Murff HJ, et al. Cancer Causes Control. 2018 Sep;29(9):823-832. doi: 10.1007/s10552-018-1058-4. Epub 2018 Jul 18. Cancer Causes Control. 2018. PMID: 30022336 Free PMC article.
Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-diethyl dithioacetal in diabetic mice.
Gruzman A, Elgart A, Viskind O, Billauer H, Dotan S, Cohen G, Mishani E, Hoffman A, Cerasi E, Sasson S. Gruzman A, et al. J Cell Mol Med. 2012 Mar;16(3):594-604. doi: 10.1111/j.1582-4934.2011.01340.x. J Cell Mol Med. 2012. PMID: 21564514 Free PMC article.
Metformin for preventing the progression of chronic kidney disease.
El-Damanawi R, Stanley IK, Staatz C, Pascoe EM, Craig JC, Johnson DW, Mallett AJ, Hawley CM, Milanzi E, Hiemstra TF, Viecelli AK. El-Damanawi R, et al. Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013414. doi: 10.1002/14651858.CD013414.pub2. Cochrane Database Syst Rev. 2024. PMID: 38837240 Review.
Allele and genotype frequency of a genetic variant in ataxia telangiectasia mutated gene affecting glycemic response to metformin in South Indian population.
Vilvanathan S, Gurusamy U, Mukta V, Das AK, Chandrasekaran A. Vilvanathan S, et al. Indian J Endocrinol Metab. 2014 Nov;18(6):850-4. doi: 10.4103/2230-8210.119944. Indian J Endocrinol Metab. 2014. PMID: 25364682 Free PMC article.
Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.
Yung MM, Ngan HY, Chan DW. Yung MM, et al. Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):301-17. doi: 10.1093/abbs/gmv128. Epub 2016 Jan 12. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26764240 Free PMC article. Review.

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target - PubMed (original) (raw)